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Abstract
Background: A remarkable range of biological functions have been ascribed to resveratrol. Recently, this
polyphenol has been shown to have body fat lowering effects. The aim of the present study was to assess some
of the potential underlying mechanisms of action which take place in adipose tissue.
Methods: Sixteen male Sprague-Dawley rats were randomly divided into two groups: control and treated with 30
mg resveratrol/kg body weight/d. All rats were fed an obesogenic diet and after six weeks of treatment white
adipose tissues were dissected. Lipoprotein lipase activity was assessed by fluorimetry, acetyl-CoA carboxylase by
radiometry, and malic enzyme, glucose-6P-dehydrogenase and fatty acid synthase by spectrophotometry. Gene
expression levels of acetyl-CoA carboxylase, fatty acid synthase, lipoprotein lipase, hormone-sensitive lipase, adipose
triglyceride lipase, PPAR-gamma, SREBP-1c and perilipin were assessed by Real time RT-PCR. The amount of
resveratrol metabolites in adipose tissue was measured by chromatography.
Results: There was no difference in the final body weight of the rats; however, adipose tissues were significantly
decreased in the resveratrol-treated group. Resveratrol reduced the activity of lipogenic enzymes, as well as that of
heparin-releasable lipoprotein lipase. Moreover, a significant reduction was induced by this polyphenol in
hormone-sensitive lipase mRNA levels. No significant changes were observed in other genes. Total amount of
resveratrol metabolites in adipose tissue was 2.66 ± 0.55 nmol/g tissue.
Conclusions: It can be proposed that the body fat-lowering effect of resveratrol is mediated, at least in part, by a
reduction in fatty acid uptake from circulating triacylglycerols and also in de novo lipogenesis.
Background
Overweight and obesity are a major public health con-
cern because they are spreading throughout the world
across all age barriers, afflicting not only adults but also
many children and adolescents. Moreover, obesity is
associated with several chronic diseases, such as dia-
betes, stroke and hypertension [1]. Considerable efforts
are being made to identify and characterize novel natu-
rally-occurring molecules which are orally active and
safe and can be employed for obesity prevention, using
a broad range of in vivo and in vitro methodologies. In
this context, polyphenols make up one of the molecule
groups most frequently studied in recent years.
Resveratrol (trans-3,5,4’-trihydroxystilbene) is a phyto-
laexin polyphenolic compound occurring naturally in
various plants, including grapes, berries and peanuts, in
response to stress, as a defence mechanism against fun-
gal, viral, bacterial infections and damage from exposure
to ultraviolet radiation [2]. Moreover, this compound is
now available in tablets on the market.
A remarkable range of biological functions have been
ascribed to this molecule. For example, it acts as a can-
cer chemoprevention agent, a powerful anti-inflamma-
tory factor and an antioxidant [3,4]. Its cardiovascular
properties, including inhibition of platelet aggregation
and promotion of vasodilation, by enhancing the pro-
duction of nitric oxide, have also been described [5].
More recently, resveratrol has been proposed as a
potential anti-obesity compound. It seems to mimic the
effects of energy restriction, thus leading to reduced
body fat and improved insulin sensitivity [6-13].
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Several mechanisms have been proposed to explain
the body fat-lowering effect of resveratrol. It should be
emphasized that a great deal of work has been devel-
oped in isolated adipocytes, thus limiting the extrapola-
tion of the results to the in vivo situation. In this
context, results coming from in vitro studies, performed
in adipocyte types (3T3-L1 cells, pig adipocytes and
human adipocytes) have shown that resveratrol
increases apoptosis [14,15], decreases proliferation and
differentiation of pre-adipocytes [16-18] and reduces
lipogenesis [18]. Moreover, in in vivo and ex vivo
experiments resveratrol has been shown to increase
mitochondrial biogenesis, thus increasing fatty acid oxi-
dation, and to enhance epinephrine-induced lipolysis
[8,10,19].
Taking that into consideration, in the present study
we aimed to gain more insight on mechanisms of action
underlying the reduction in body fat induced by resvera-
trol, which take place in adipose tissue at the level of
enzyme activities and gene expression.
Methods
Animals, diets and experimental design
The experiment was conducted with sixteen male
Sprague-Dawley rats with an initial body weight of 180
± 2 grams purchased from Harlan Ibérica (Barcelona,
Spain) and took place in accordance with the institu-
tion’s guide for the care and use of laboratory animals,
with the approval of our internal animal ethics Com-
mittee (Reference protocol approval CUEID CEBA/30/
2010), following European Community Council Direc-
tive. The rats were individually housed in polycarbo-
nate metabolic cages (Techniplast Gazzada,
Guguggiate, Italy) and placed in an air-conditioned
room (22 ± 2°C) with a 12 h light-dark cycle. After a
6 d adaptation period, rats were randomly divided in 2
dietary groups of eight animal each (Control and
Resveratrol) and fed on a commercial obesogenic diet,
high in sucrose (20.0%) and fat (22.5%) (Harlan Iberica,
TD.06415). Due to the fact that in a previous study
from our laboratory we observed a body-fat lowering
effect of resveratrol at a dose of 30 mg/kg/d [20], this
dose was used in the present study. Resveratrol was
added to the diet, as previously reported in the men-
tioned paper [20]. All animals had free access to food
and water. Food intake and body weight were mea-
sured daily.
At the end of the experimental period (6 weeks) ani-
mals were sacrificed, under anaesthesia (chloral
hydrate) by cardiac exsanguination, between 9.00 a
12.00 a.m. White adipose tissue from different anato-
mical locations (perirenal, epididymal, mesenteric and
subcutaneous) was dissected, weighed and immediately
frozen.
Extraction and analysis of RNA and quantification by
reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was isolated from 100 mg of epididymal adi-
pose tissue using Trizol (Invitrogen, Carlsbad, California,
USA), according to the manufacturer’s instructions.
RNA samples were then treated with DNA-free kit
(Ambion, Applied Biosystems, Austin, Texas, USA) to
remove any contamination with genomic DNA. The
yield and quality of the RNA were assessed by measur-
ing absorbance at 260, 270, 280 and 310 nm and by
electrophoresis on 1.3% agarose gels. 1.5 μg of total
RNA of each sample was reverse-transcribed to first-
strand complementary DNA (cDNA) using iScript™
cDNA Synthesis Kit (Bio-Rad, Hercules, California,
USA).
Relative acetyl-CoA carboxylase (ACC), fatty acid
synthase (FAS), sterol-regulatory element binding pro-
tein-1c (SREBP-1c), adipose triglyceride lipase (ATGL),
hormone sensitive lipase (HSL), Perilipin, LPL and per-
oxisome proliferator-activated receptor g (PPARg)
mRNA levels were quantified using Real-time PCR with
an iCycler™ - MyiQ™ Real time PCR Detection System
(BioRad). b-actin mRNA levels were similarly measured
and served as the reference gene.
Quantification of ACC, FAS, SREBP-1c, ATGL, Perili-
pin, LPL, PPARg and b-actin by SYBR® Green chemical
Real time PCR: 0.1 μL of each cDNA were added to PCR
reagent mixture, SYBR® Green Master Mix (Applied Bio-
systems), with the sense and antisense primers (300 nM
each). The PCR parameters were as follows: initial 2 min
at 50°C, denaturation at 95°C for 10 min followed by 40
cycles of denaturation at 95°C for 15s, annealing for 30s
and extension at 60°C for 30s. Information concerning
specific sense/antisense primers and PCR annealing tem-
peratures are described in Table 1.
Quantification of HSL and b-actin by Taqman Real
Time PCR: in the case of b-actin, 1 μL of each cDNA
was added to PCR reagent mixture, Premix Ex TaqTM
(Takara, Madison, Wisconsin, USA), with the sense
(300 nM b-actin) and antisense primers (300 nM b-
actin) and probe (0.5 μM b-actin). Specific primers were
designed and synthesized commercially (Eurogentec,
Liège, Belgium) and the sequences were as follows:
b-actin: 5’- TCT ATG AGG GCT ACG CTC TCC -3’
(forward)
5’- CAC GCT CGG TCA GGA TCT TC -3’
(reverse)
5’- FAM- CCT GCG TCT GGA CCT GGC TGG
C -TAMRA-3’ (probe)
For HSL mRNA levels 2 μL of each cDNA was added
to PCR reagent mixture, TaqMan® Universal PCR Mas-
ter Mix, (Applied Biosystems), with 20X TaqMan® Gene
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Expression Assay Mix containing specific primers and
probes (Rn 00563444; Applied Biosystems).
The PCR parameters were as follows: denaturation at
95°C for 15s for b-actin and for 10 min for HSL, fol-
lowed by 40 cycles of denaturation at 95°C for 5 s for b-
actin and 15s for HSL and combined annealing and
extension at 60°C for 30s for b-actin and 60s for HSL.
Gene expression analysis was performed using the
Comparative threshold cycle (Ct) method [21]. Amplifi-
cation of b-actin sequence was performed in parallel
and was used to normalize values obtained for target
genes.
Enzyme activities
For total lipoprotein lipase (LPL) activity determination,
homogenates of epididymal adipose tissue (250 mg) were
prepared in 750 μL of 10 mM HEPES buffer (pH 7.5) con-
taining 1 mM DTT, 1 mM EDTA, 250 mM sucrose and 2
g/L heparin and used as enzyme source. For heparin-relea-
sable LPL (HR-LPL) activity determination, 250 mg of adi-
pose tissue were incubated in 750 μL of 10 mM HEPES
buffer (described above) at 37°C during 30 min.
Enzyme activity was assessed following the method
described by Del Prado et al. [22], with modifications
[23]. Total LPL and HR-LPL activities were calculated by
subtracting non-LPL lipolytic activity in the presence of
NaCl from the total lipolytic activity, determined without
NaCl. Both total and HR-LPL activities were expressed as
nmol oleate released per minute per gram of tissue.
For lipogenic enzyme analysis, 1 g of adipose tissue
was homogenized in 5 mL of buffer (pH 7.6) containing
150 mM KCl, 1 mM MgCl2, 10 mM N-acetyl-cysteine
and 0.5 mM dithiothreitol. After centrifugation at 100
000 g for 40 min at 4°C, the supernatant fraction was
used for quantification of enzyme activities. Acetyl-CoA
carboxylase (ACC, E.C. 6.4.1.2), fatty acid synthase (FAS,
E.C. 2.3.1.85), glucose-6-phosphate dehydrogenase
(G6PDH, E.C. 1.1.1.49) and malic enzyme (ME, E.C.
1.1.1.40) activities were measured as previously
described [24]. Enzyme activities were expressed as
follows: nmol NADPH consumed per minute per mg of
protein for FAS, as nmol NADPH produced per minute
per mg of protein for G6PDH and ME, and as nmol
bicarbonate incorporated/min, per mg protein for ACC.
Sample preparation and determination of resveratrol
metabolites in adipose tissue
Analysis was carried out by (LC-MS/MS) after a solid-
phase extraction (SPE), as described previously by Urpí-
Sardà et al. and Andres-Lacueva et al. [25-27]. Liquid
chromatography-tandem MS Liquid chromatography
analyses were performed using an ACQUITY UPLC
(Waters, Mildford, Massachusetts, USA) and a triple
quadrupole mass spectrometer (API 3000) from Applied
Biosystems (PE Sciex, Concord, ON, Canada), equipped
with a Turbo IonSpray source operated in the negative-
ion mode. For quantification of resveratrol metabolites
in tissue samples, the multiple reaction monitoring
(MRM) mode was used. All of them were quantified
using a six-point calibration curve between 0.1 and 10
μg/g determined by weighted (1/x2) linear regression.
The total amount of resveratrol metabolites was
expressed as nanogram of trans-resveratrol equivalents
per gram of tissue. The precision and accuracy of the
method met the criteria of that validated by Urpí-Sardà
et al. [26]. The Limit Of Detection (LOD) of the method
was 0.045 μg/g and the Limit Of Quantitation (LOQ)
was 0.1 μg/g.
Statistical analysis
Results are presented as means ± standard error of the
means. Statistical analysis was performed using SPSS
17.0 (SPSS Inc. Chicago, Illinois, USA). Data were ana-
lysed by Student’s t test. Statistical significance was set-
up at the P < 0.05 level.
Results
Body weight, food intake and white adipose tissue
weights
No statistical differences in food intake (P = 0.79), final
body weight (P = 0.62) and body weight gain (P = 0.65)
Table 1 Primers and annealing temperatures for PCR amplification of each gene studied
SYBR® Green RT-PCR:
Primers Sense primer Antisense primer Annealing Temperature
ACC 5’-GGACCACTGCATGGAATGTTAA-3’ 5’-TGAGTGACTGCCGAAACATCTC-3’ 60.6°C
FAS 5’-AGC CCC TCA AGT GCA CAG TG-3’ 5’-TGCCAATGTGTTTTCCCTGA-3’ 60.0°C
SREBP-1c 5’-GCGGACGCAGTCTGGG-3’ 5’-ATGAGCTGGAGCATGTCTTCAAA-3’ 67.3°C
ATGL 5’-CACTTTAGCTCCAAGGATGA-3’ 5’-TGGTTCAGTAGGCCATTCCT-3’ 62.0°C
Perilipin 5’-AGAGGAGACAGATGAGGAGGAAG -3’ 5’-AGATGGTGTTCTGCAGAGTCTTC -3’ 63.9°C
LPL 5’- CAGCTGGGCCTAACTTTGAG -3’ 5’- CCTCTCTGCAATCACACGAA -3’ 61.5°C
PPARg 5’-ATTCTGGCCCACCAACTTCGG -3’ 5’-TGGAAGCCTGATGCTTTATCCCCA -3’ 64.5°C
b-Actin 5’-ACGAGGCCCAGAGCAAGAG-3’ 5’-GGTGTGGTGCCAGATCTTCTC-3’ 60.0°C
ACC, acetyl-CoA carboxylase; FAS, fatty acid synthase; SREBP-1c, sterol-regulatory element binding protein-1c; ATGL, adipose triglyceride lipase; LPL, lipoprotein
lipase; PPAR, peroxisome proliferator-activated receptor.
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were found between experimental groups (Figure 1).
Nevertheless, resveratrol significantly reduced adipose
tissue (AT) weight in the four anatomical locations ana-
lysed (Figure 2). The magnitude of this reduction was as
follows: 22.2% in perirenal AT, 21.2% in epididymal AT,
22.8% in mesenteric AT and 30.5% in subcutaneous AT.
Enzyme activities in adipose tissue
Only HR-LPL, the active fraction of the enzyme, was sig-
nificantly reduced in resveratrol-treated rats (P < 0.05)
(Figure 3). With regard to enzymes involved in de novo
lipogenesis, rats fed the resveratrol-supplemented diet
showed significantly reduced activities for G6PDH (P <
0.05), FAS (P < 0.01) and ACC (P < 0.01) (Figure 4).
Enzyme and transcription factor expressions in adipose
tissue
No significant changes were induced by resveratrol feeding
in the expression of lipogenic enzymes (ACC and FAS)
and LPL or the transcriptional factors regulating their
activities, SREBP-1c and PPARg. As far as lipases are con-
cerned, although ATGL expression was not changed, in
the case of HSL a significant decrease in Ct was observed,
indicating that this lipase expression was raised by resvera-
trol. Finally, the expression of perilipin, a protein involved
in the lipolytic process, was not modified (Table 2).
Resveratrol and its metabolites in adipose tissue
Trans-resveratrol was not present in adipose tissue but
several glucuronide and sulfate metabolites were found
(i.e. trans-resveratrol-3-O-glucuronide, trans-resveratrol-
3-sulfate, trans- resveratrol-4’-sulfate, cis-resveratrol-3-
sulfate; trans-resveratrol-3,4-disulfate). The total amount
of resveratrol metabolites found in adipose tissue from
treated animals, expressed as resveratrol equivalents,
was 2.66 ± 0.55 nmol/g tissue.
Discussion
As explained in the introduction section, in recent years
resveratrol has come to be a molecule of potential inter-
est in reducing body fat. Nevertheless, information con-
cerning the effects of resveratrol in animal models is
rather scant.
In general terms, our results reporting a reduction in
body fat in rats fed on a diet supplemented with
Figure 1 Food intake, final body weight and body weigt gain.
Values are means for eight animals per group with the standard
errors of the means, shown by vertical bars.
Figure 2 White adipose tissue weights in experimental groups.
Values are means for eight animals per group with the standard
errors of the means, shown by vertical bars. *P < 0.05; **P < 0.01.
PR: perirenal; EP: epididymal; MS: mesenteric; SC: subcutaneous.
Figure 3 Total and heparin-releasable (HR) lipopoprotein lipase
activities in adipose tissue. Values are means for eight animals per
group with the standard errors of the means, shown by vertical
bars. *P < 0.05.
Figure 4 Lipogenic enzyme activities in adipose tissue. Values
are means for eight animals per group with the standard errors of
the means, shown by vertical bars. *P < 0.05; **P < 0.01. G6PDH:
Glucose-6P-dehydrogenase; ME: malic enzyme; FAS: fatty acid
synthase; ACC: acetyl-CoA-Carboxylase.
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resveratrol are in good accordance with those published
by other authors [8,11-13]. It is important to point out
that the effective dose in our experimental design, as
well as those used by other authors, is far greater than
the amount usually ingested by humans (100-930 μg/d)
[28,29], meaning that the positive effects of this mole-
cule on body fat would only be achieved by the intake
of resveratrol pills or functional foods enriched with this
molecule.
The amount of triacylglycerols accumulated in adipose
tissue results from the balance among several metabolic
pathways which take place in the tissue, such as de novo
lipogenesis, fatty acid uptake from circulating triacylgly-
cerols and lipid mobilization. In order to shed light onto
the reasons that can explain the reduction in body fat
achieved by resveratrol, the effects of this molecule on
these pathways were assessed.
To evaluate the effect on fatty acid uptake from circu-
lating triacylglycerols the activities of total LPL and
heparin-releasable LPL (HR-LPL) were measured. As far
as we know this is the first study which addresses the
effects of resveratrol on this enzyme activity. Heparin-
releasable LPL, the active form of this enzyme which is
placed in adipose tissue endothelium, was significantly
reduced by resveratrol. By contrast, when the expression
of LPL and PPARg, the transcriptional factor that regu-
lates its activity, were measured no significant changes
were observed. These data suggest that the effect of
resveratrol on adipose tissue is mediated, at least in
part, by a reduction in fatty acid uptake from triacylgly-
cerols in circulating lipoproteins, and that the effect on
LPL occurs at a post-transcriptional level. As far as we
know this is the first study which addresses the effects
of resveratrol on this enzyme activity.
With regard to de novo lipogenesis, in the present
study a significant reduction was observed in the activity
of FAS and G6PDH. The effects of resveratrol on
G6PDH and FAS activities cannot be compared with
other data in the literature because the effects of this
polyphenol on these enzyme activities have not been
addressed so far. The effect of resveratrol on ACC is in
good accordance with the results previously reported by
Rivera et al. in obese Zuker rats [11].
When we analysed the expressions of ACC and FAS
we found that they were not modified by resveratrol, in
line with the lack of change in SREBP-1c expression.
Thus, our results suggest that, under the present experi-
mental conditions, reduced lipogenesis contributes to
the reduction in body fat induced by resveratrol, and
that the effects on ACC and FAS occur, as well as in
LPL, at a post-transcriptional level. It the case of ACC,
it has been reported that the phosphorylation/despho-
sphorylation process regulated by AMPK plays a crucial
role in the control of enzyme activity [30]. In this con-
text, it is noteworthy that resveratrol has been reported
to activate AMPK [11,12]. With regard to FAS, although
one of the most important regulatory mechanisms for
this enzyme takes place at the transcriptional level,
other post-transcriptional mechanisms also contributes
to enzyme activity regulation [31,32].
The effects of resveratrol on lipolysis have been ana-
lysed by Szkudelska et al. [33]. They observed enhanced
lipolytic response to epinephrine induced by resveratrol.
They suggested that this effect results, at least partially,
from increased cAMP in adipocytes. Although it is well
known that the main mechanism by which lipases are
activated is phosphorylation, in order to gain more
insight concerning the effects of resveratrol on this
metabolic pathway, in the present study the expression
of the two main adipose tissue lipases was measured.
No changes were observed in mRNA levels of ATGL.
By contrast, consistent with the previous demonstration
of a positive effect of resveratrol on lipolysis [33], HSL
expression was increased in resveratrol-treated animals,
showing that this molecule acts differently on both
lipases.
The effect of resveratrol on the expression of perilipin
was also analysed. Resveratrol did not modify perilipin
expression, suggesting that an effect on this protein
does not underly the reduction in adipose tissue weight
induced by resveratrol. Nevertheless, potential changes
in perilipin phospohorylation cannot be discarded.
Some of the results related to the effects of resveratrol
on gene expression in the present work are not in good
accordance with some published studies performed in
cultured cells. Thus, Rayalam et al. [14], reported that
resveratrol repressed PPARg, SREBP-1, FAS, LPL and
HSL in 3T3-L1 adipocytes when these cells were incu-
bated with 25 μM resveratrol. Floyd et al. [34] also
found reduced expression of PPARg and LPL in 3T3-L1
adipocytes treated with 50 μM resveratrol. The discre-
pancy between in vitro results and those reported in the
present study is probably due to the fact that the resver-
atrol concentrations used with isolated cells, 25-50 μM,
exceed the amount of this polyphenol usually found in
Table 2 mRNA levels in adipose tissue
Control Resveratrol
ACC 4.13 ± 0.57 4.02 ± 0.445 NS
FAS 1.91 ± 0.65 1.83 ± 0.74 NS
LPL 6.92 ± 0.43 7.00 ± 1.02 NS
SREBP-1c 3.23 ± 0.77 3.88 ± 0.69 NS
PPARg 6.66 ± 0.49 6.56 ± 1.26 NS
HSL 4.65 ± 0.54a 1.99 ± 0.38b P <0.05
ATGL 5.44 ± 0.42 5.64 ± 0.73 NS
Perilipin 1.73 ± 0.44 3.02 ± 0.60 NS
Values are given as Ct means ± standard errors of the mean (n = 8).
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blood after oral resveratrol administration (1.2-1.5 μM)
[35,36], and consequently that reaching adipose tissue in
vivo. In the present study trans-resveratrol was not
found in adipose tissue due to its very short half life,
but the total average amount of resveratrol metabolites
in this tissue after treatment with resveratrol at a dose
of 30 mg resveratrol/kg body weight/day was only 2.66
nmol/g. In addition, it is important to take into account
that adipocytes are exposed to a great amount of
changes in physiological stimuli under in vivo condi-
tions, which are not considered in in vitro studies.
Thus, it should be emphasized that although some of
the results obtained in in vitro studies by using isolated
cells are quite promising and suggest the anti-obesity
effect of resveratrol, it is important to be cautious and
to check both the effects as well as the mechanisms of
action, firstly in animal models and then in humans.
Conclusion
Taken together, the results of the present work suggest
that the body fat-lowering effect of resveratrol is
mediated, at least in part, by a reduction in fatty acid
uptake from circulating triacylglcyerols, as well as in de
novo lipogenesis in adipose tissue. Nevertheless, some
actions of this polyphenol on organs and tissues with a
relevant role in triacylglycerol metabolism, such as liver
and skeletal muscle, should also be considered. These
should be further investigated in order to determine its
whole body-fat mechanism of action.
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